Kenji Shimizu

11.1k total citations · 2 hit papers
221 papers, 8.9k citations indexed

About

Kenji Shimizu is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Kenji Shimizu has authored 221 papers receiving a total of 8.9k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Molecular Biology, 59 papers in Oncology and 33 papers in Immunology. Recurrent topics in Kenji Shimizu's work include RNA modifications and cancer (38 papers), Cancer-related gene regulation (28 papers) and Immune Cell Function and Interaction (21 papers). Kenji Shimizu is often cited by papers focused on RNA modifications and cancer (38 papers), Cancer-related gene regulation (28 papers) and Immune Cell Function and Interaction (21 papers). Kenji Shimizu collaborates with scholars based in Japan, United States and China. Kenji Shimizu's co-authors include Mitchell Goldfarb, Michael Wigler, Mamoru Ouchida, Elizabeth J. Taparowsky, Manuel Perucho, Takumi Maruhashi, Taku Okazaki, Daisuke Sugiura, Il‐mi Okazaki and Ottavio Fasano and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Kenji Shimizu

211 papers receiving 8.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change

1982 596 citations Kenji Shimizu et al. profile →
Structure and activation of the human N-ras gene

1983 460 citations Kenji Shimizu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kenji Shimizu Japan	48	5.0k	3.0k	1.6k	1.3k	1.0k	221	8.9k
Manabu Fukumoto Japan	52	4.3k 0.9×	2.5k 0.9×	1.2k 0.8×	1.6k 1.3×	1.3k 1.2×	319	9.5k
Yoichi Furukawa Japan	48	6.5k 1.3×	2.3k 0.8×	1.1k 0.7×	1.6k 1.2×	794 0.8×	183	9.6k
Kevin Shannon United States	58	6.2k 1.2×	2.2k 0.8×	1.6k 1.0×	871 0.7×	1.1k 1.1×	276	12.5k
Ulrike Stein Germany	50	4.1k 0.8×	2.4k 0.8×	700 0.4×	1.3k 1.0×	1.2k 1.2×	222	7.6k
Bharat Jasani United Kingdom	49	3.1k 0.6×	2.6k 0.9×	981 0.6×	1.3k 1.1×	1.0k 1.0×	225	7.9k
Mahmoud Ghandi United States	14	5.5k 1.1×	2.1k 0.7×	1.6k 1.0×	2.2k 1.7×	1.7k 1.7×	27	8.9k
Pier Giorgio Natali Italy	61	5.3k 1.0×	3.1k 1.1×	2.6k 1.6×	1.3k 1.1×	984 1.0×	260	11.3k
Philip J. Coates United Kingdom	49	4.5k 0.9×	3.1k 1.0×	1.0k 0.6×	1.3k 1.1×	1.2k 1.1×	205	9.4k
Changshun Shao China	53	5.3k 1.0×	2.0k 0.7×	1.9k 1.2×	2.0k 1.6×	662 0.6×	190	9.9k
Gerard C. Blobe United States	52	6.6k 1.3×	3.0k 1.0×	919 0.6×	1.4k 1.1×	1.2k 1.2×	135	10.4k

Countries citing papers authored by Kenji Shimizu

Since Specialization

Citations

This map shows the geographic impact of Kenji Shimizu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenji Shimizu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenji Shimizu more than expected).

Fields of papers citing papers by Kenji Shimizu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenji Shimizu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenji Shimizu. The network helps show where Kenji Shimizu may publish in the future.

Co-authorship network of co-authors of Kenji Shimizu

This figure shows the co-authorship network connecting the top 25 collaborators of Kenji Shimizu. A scholar is included among the top collaborators of Kenji Shimizu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenji Shimizu. Kenji Shimizu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shimizu, Kenji, et al.. (2026). Identification of 5’ untranslated region variants in genes involved in neurodevelopmental disorders. Journal of Human Genetics.

Iseki, Masako, Takenobu Yamamoto, Youichi Ogawa, et al.. (2023). Efficacy and safety of intravenous fosphenytoin for patients with acute herpes zoster‐associated pain: A placebo‐controlled randomized trial. The Journal of Dermatology. 51(2). 234–242. 2 indexed citations

Sugiura, Daisuke, Il‐mi Okazaki, Takumi Maruhashi, et al.. (2022). PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity. Nature Immunology. 23(3). 399–410. 57 indexed citations

Jin, Jianshi, Taisaku Ogawa, Kirill Kryukov, et al.. (2022). Robotic data acquisition with deep learning enables cell image–based prediction of transcriptomic phenotypes. Proceedings of the National Academy of Sciences. 120(1). e2210283120–e2210283120. 14 indexed citations

Maruhashi, Takumi, Daisuke Sugiura, Il‐mi Okazaki, et al.. (2022). Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity. Immunity. 55(5). 912–924.e8. 129 indexed citations

Shimizu, Kenji, Daisuke Sugiura, Il‐mi Okazaki, et al.. (2021). PD-1 preferentially inhibits the activation of low-affinity T cells. Proceedings of the National Academy of Sciences. 118(35). 14 indexed citations

Nagai, Jun, Riho Kurata, Kenji Shimizu, et al.. (2020). Establishment of Novel High-Standard Chemiluminescent Assay for NTPase in Two Protozoans and Its High-Throughput Screening. Marine Drugs. 18(3). 161–161. 4 indexed citations

Sugiura, Daisuke, Takumi Maruhashi, Il‐mi Okazaki, et al.. (2019). Restriction of PD-1 function by cis -PD-L1/CD80 interactions is required for optimal T cell responses. Science. 364(6440). 558–566. 285 indexed citations

Maruhashi, Takumi, et al.. (2018). LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII. Nature Immunology. 19(12). 1415–1426. 202 indexed citations

10.

Tang, Ce, Shigeru Kakuta, Kenji Shimizu, et al.. (2018). Suppression of IL-17F, but not of IL-17A, provides protection against colitis by inducing Treg cells through modification of the intestinal microbiota. Nature Immunology. 19(7). 755–765. 132 indexed citations

11.

Rai, Kammei, Nagio Takigawa, Sachio Ito, et al.. (2011). Liposomal Delivery of MicroRNA-7–Expressing Plasmid Overcomes Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistance in Lung Cancer Cells. Molecular Cancer Therapeutics. 10(9). 1720–1727. 110 indexed citations

12.

Oka, Takashi, Kana Washio, Masayuki Takano, et al.. (2009). Multi-Step Aberrant CpG Island Hyper-Methylation Is Associated with the Progression of Adult T–Cell Leukemia/Lymphoma. American Journal Of Pathology. 176(1). 402–415. 58 indexed citations

13.

Gündüz, Mehmet, Esra Gündüz, Ryo Tamamura, et al.. (2008). Lack of B-RAF Mutations in Head and Neck Squamous Cell Carcinoma. Folia Biologica. 54(5). 157–161. 5 indexed citations

14.

Chintala, Madhu, et al.. (2008). Basic and Translational Research on Proteinase-Activated Receptors: Antagonism of the Proteinase-Activated Receptor 1 for Thrombin, a Novel Approach to Antiplatelet Therapy for Atherothrombotic Disease. Journal of Pharmacological Sciences. 108(4). 433–438. 42 indexed citations

15.

Kubo, Takafumi, Hiromasa Yamamoto, William W. Lockwood, et al.. (2008). MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. International Journal of Cancer. 124(8). 1778–1784. 117 indexed citations

16.

Kanzaki, Hirotaka, Mamoru Ouchida, Hiroko Hanafusa, et al.. (2007). The association between RAD18 Arg302Gln polymorphism and the risk of human non-small-cell lung cancer. Journal of Cancer Research and Clinical Oncology. 134(2). 211–217. 10 indexed citations

17.

Elnemr, Ayman, Tomohiko Ohta, Tohru Tani, et al.. (2001). Anomalous pancreaticobiliary ductal junction without bile duct dilatation in gallbladder cancer.. PubMed. 48(38). 382–6. 22 indexed citations

18.

Tsukamoto, K., et al.. (1998). TR-IA4号機特集 Transient Crystal Growth Rate in Microgravity:Report from TR-IA-4 Rocket Experiment. 15(1). 2–9.

19.

Shimizu, Kenji, et al.. (1989). Inhibition of growth of some enteropathogenic strains in mixed cultures of Streptococcus faecalis and Clostridium butyricum. 40(159). 151–160. 9 indexed citations

20.

Lewis, John A., Kenji Shimizu, & David Zipser. (1983). Isolation and Preliminary Characterization of the Chinese Hamster Thymidine Kinase Gene. Molecular and Cellular Biology. 3(10). 1815–1823. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact